|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hypoglycemia rates were lower with IDegLira versus basal insulin and higher versus unchanged GLP-1RA (estimated rate ratios, 0.5 [0.2; 1.6]<sub>95% CI</sub> [ P = .242]; 0.3 [0.1; 0.5]<sub>95% CI</sub> [ P<.001], and 11.8 [3.3; 42.8]<sub>95% CI</sub> [ P<.001] for DUAL II, V, and III, respectively).
|
30383495 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1As decreased risks of all-cause and CV mortality and severe hypoglycemia, whereas DPP-4Is had no effect on CV outcomes but increased risks in acute pancreatitis and hypoglycemia.
|
28249585 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 agonists yield greater reduction in HbA1c and weight as compared to DPP-4 inhibitors, with increased incidence of gastrointestinal symptoms but not hypoglycaemia.
|
29364587 |
2018 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 therapy has the potential to lower glucose without causing hypoglycaemia.
|
29866735 |
2018 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
GLP-1 RA intensifiers had equivalent glycemic control to RAI or other injectables, with a nonsignificantly lower risk of hypoglycemia and reduction in body weight.
|
29975575 |
2018 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
GLP-1RAs are generally well tolerated, with gastrointestinal and injection-site reactions being the most troublesome drug-related adverse events, and are associated with a very low intrinsic risk of hypoglycaemia.
|
31317516 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1RAs may be considered in combination with other glucose-lowering medications because of their ability to lower glucose in a glucose-dependent manner, lowering their risk for hypoglycemia, while improving some cardiorenal risk factors.
|
31318152 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A short-acting GLP-1RA plus basal insulin is an alternative to premixed insulin, resulting in better efficacy and a lower risk of hypoglycemia and weight gain.
|
30859500 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Addition of GLP-1 RA to basal insulin provided improved glycemic control, led to weight reduction and similar hypoglycemia rates versus an intensified insulin strategy; however, symptomatic hypoglycemia rates were significantly lower when compared with a basal insulin plus RAI.
|
28294702 |
2017 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As its glucose-lowering action is glucose dependent, a GLP-1 receptor agonist (GLP-1RA) achieves these benefits with a lower risk of hypoglycemia compared with other diabetes therapies.
|
28721686 |
2017 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Besides improving glycemic control, the GLP-1RAs have other beneficial effects such as weight loss and a low risk of hypoglycemia.
|
28102093 |
2017 |
|
Hypoglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BI in combination with GLP-1 RAs appears to be an effective intensification strategy, further reducing A1C levels and hypoglycemia frequency compared to increasing BI doses.
|
28816532 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Commentary on 'Effects of GLP-1 on counter-regulatory responses during hypoglycemia after GBP surgery'.
|
31370002 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia.
|
27975209 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetes increases the severity of impairment in PD, and GLP-1 improve it through its direct neuronal effect in addition to its indirect effect through producing hypoglycemia.
|
31654678 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of GLP-1 on counter-regulatory responses during hypoglycemia after GBP surgery.
|
31176298 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Expert opinion: IDegLira provides superior glycaemic control and mitigates the primary adverse effects associated with insulin therapy (weight gain and hypoglycaemia) and GLP-1RAs (gastrointestinal side effects) with no indication of additive effects.
|
28150516 |
2017 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Glucagon like peptide 1 receptor agonists (GLP-1 RAs) are also effective in terms of glycemic control and associated with weight loss and low risk of hypoglycemia.
|
29636825 |
2018 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Glucagon-like peptide 1 receptor agonists (GLP1-RA) are prominent agents in the therapeutics of type 2 diabetes mellitus due to their exemplary efficacy in both preprandial and postprandial glycemia, their safety, low risk of hypoglycemia, their multilevel pathophysiological superiority, weight loss and importantly the observed benefits in cardiovascular disease reduction.
|
31686781 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are emerging as an important therapy to consider for patients with type 2 diabetes (T2D) given this class of treatment's ability to reduce glycated haemoglobin and their associated weight loss and low risk for hypoglycaemia.
|
31801807 |
2020 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose cotransporter 2 inhibitors (SGLT2i) are of particular interest in type 2 diabetes treatment strategies, due to their efficacy in reducing HbA1c with a low risk of hypoglycaemia, to their positive effects on body weight and blood pressure and in light of their effects on cardiovascular risk and on nephroprotection emerged from the most recent cardiovascular outcome trials.
|
29334278 |
2018 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide an alternative to prandial insulin, with the benefits of fewer daily injections, and a lower risk of hypoglycemia and weight gain.
|
30610613 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) exert potent glucose-lowering effects without increasing risks for hypoglycemia and weight gain.
|
30860874 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1RA) are drugs used in type 2 diabetes that have a low risk of hypoglycemia and have been shown to exert neuroprotective effects.
|
31518433 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a study comparing the addition of exenatide QW and pioglitazone with the addition of basal-bolus insulin in 101 people receiving sulfonylureas and metformin with baseline HbA1c >10%, HbA1c fell from >11% by >4% compared with <4%, respectively, and the GLP-1RA plus thiazolidinedione treatment was associated with less weight gain and hypoglycemia.What can we conclude?
|
28589542 |
2017 |